| Jul 18 |
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
|
| Jul 15 |
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
|
| Jun 12 |
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
|
| Jun 3 |
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
|
| May 23 |
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 20 |
Dow Falls Over 150 Points; Sohu Posts Q1 Loss
|
| May 20 |
Nasdaq Surges 100 Points; Wix.com Shares Jump Following Q1 Results
|
| May 20 |
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
|
